Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

2014 ASCO Annual Meeting

Published: 31 May 2014

Rating:

Save

Dr John Byrd - The Ohio State University, Columbus, USA

At a press conference at ASCO 2014, Dr Byrd presents the early findings from the phase III RESONATE study which indicate that ibrutinib yields lasting tumour responses and marked improvement in survival over standard of atumumab for patients with relapsed chronic lymphocytic leukaemia (CLL).

Read the article for more.

Related Videos

KRdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

20 Dec 2024

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

28 Oct 2024

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

28 Oct 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

15 Sep 2024

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$